Please note, this OEL/ADE monograph also applies to ipidacrine hydrochloride monohydrate (CAS RN 118499-70-0). Ipidacrine, as ipidacrine hydrochloride, is a reversible cholinesterase inhibitor indicated to treat peripheral nervous system diseases, such as neuritis, polyneuritis, polyneuropathy, polyradiculoneuropathy, myasthenia and myasthenic syndrome of various etiology; bulbar palsy and paresis; recovery period after organic CNS (Central Nervous System) lesions with motion disorders; complex therapy of demyelinating disease; memory disorders of different origins, such as Alzheimer's disease and other forms of dementia in elderly; and intestinal atony.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Ipidacrine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.